Please select a Capability in order to start your service request.
New BD Kiestra™ Urine Culture App1 Drives Increased Lab Efficiency and Impacts Patient ManagementJul 18, 2017
FRANKLIN LAKES, N.J., July 18, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new technology that can automatically report and release negative urine cultures.
Every day, medical laboratory professionals spend a significant amount of time reviewing urine samples. Because up to 70 percent of these samples yield no growth or no significant growth, professionals devote more time to non-value-added tasks rather than to complex patient samples that require expert analysis.
The BD Kiestra™ urine culture app, together with BD BBL™ plated media, uses digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean caught and catheterized samples. Using the BD Kiestra™ ReadA™ compact’s intelligent incubation and imaging device with high-throughput robotics to perform time series imaging, plates with no significant growth can be automatically released for disposal and the results reported to the customer’s compatible laboratory information system (LIS). Plates with significant growth automatically go into a queue for clinician analysis.
The definition of significant growth can be customized using patient demographics and lab-directed rules, a feature unique to this BD solution. The automatic results generated by the application elevate the entire lab automation solution into a diagnostic results generating device.
“As one of the first applications using image analysis software, the urine culture app begins the transformation of microbiology practices today,” said Steve Conly, vice president of microbiology for BD. “Being able to automatically release urine specimens with no growth or no significant growth will allow laboratories to focus on more relevant clinical tasks. BD is committed to helping improve laboratory efficiency and patient management through innovation and automated intervention.”
The BD Kiestra™ urine culture app was validated in close collaboration with the University of Ljubljana (Slovenia) and the University of Heidelberg (Germany). This technology can be used on the BD Kiestra™ WCA (work cell automation) and the BD Kiestra™ TLA (total lab automation) solutions. For more information BD Kiestra lab automation solutions, please visit: bd.com/en-us/offerings/capabilities/lab-automation/.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.